EGF and TGF-alpha Levels in Bladder Cancer
Author Information
Author(s): JK Mellon, S Cook, P Chambers, DE Neal
Primary Institution: University of Newcastle upon Tyne
Hypothesis
The study aims to quantify levels of EGF and TGF-alpha in bladder cancers and correlate this information with EGFR levels.
Conclusion
Tumour samples had significantly higher levels of TGF-alpha compared to EGF, suggesting TGF-alpha is the likely ligand for EGFR in bladder tumours.
Supporting Evidence
- TGF-alpha levels in malignant tissue were significantly higher than in benign bladder samples.
- Mean TGF-alpha of malignant tissue was 9.50 ng/g compared to 0.78 ng/g for EGF.
- EGF levels did not correlate with EGFR levels in the study.
Takeaway
This study looked at two important growth factors in bladder cancer and found that one of them, TGF-alpha, is much higher in cancerous tissue than in non-cancerous tissue.
Methodology
The study used radioimmunoassay techniques to measure EGF and TGF-alpha levels in bladder tissue samples from patients with bladder cancer.
Limitations
The study population had a relatively high proportion of muscle-invasive tumours, which may not represent all bladder cancer patients.
Participant Demographics
Patients with newly diagnosed bladder cancer requiring surgical resection or biopsy.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website